FDA Issues Warning Letters to 30 Telehealth Companies Over Compounded GLP-1 Marketing

The US Food and Drug Administration issued warning letters to 30 telehealth companies in March 2026 for making false or misleading claims about compounded GLP-1 weight-loss drugs on their websites. The action represents the second major enforcement wave since the agency began its crackdown on direct-to-consumer GLP-1 advertising in September 2025, and the volume of regulatory correspondence in the past six months has exceeded the cumulative total of the previous decade.

What Triggered the Crackdown

The enforcement surge follows the FDA's determination that the semaglutide injection drug shortage has been resolved. During the shortage, compounding pharmacies operated under an exception that allowed them to produce versions of drugs that were otherwise unavailable. With branded semaglutide supply restored, that exception has narrowed significantly.

Many telehealth companies continued marketing compounded GLP-1 drugs as though the shortage exception still applied. The FDA's warning letters specifically targeted claims that compounded products were comparable to FDA-approved medications — a characterization the agency considers misleading, since compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before being sold.

Among the companies that received warning letters was Medvi, the AI-powered telehealth startup profiled by The New York Times this week for generating $401 million in its first year with just two employees. The company is one of more than 70 telehealth firms warned by the FDA in the past six months.

The Shared Infrastructure Behind the Companies

A STAT investigation revealed that at least 30 percent of the warned telehealth companies share clinical affiliations with just four nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. These platforms provide the licensed physician networks and prescription infrastructure that telehealth brands use to operate. The overlap suggests that the FDA's regulatory scrutiny may extend beyond the consumer-facing brands to the underlying medical infrastructure providers.

Separately, the Department of Health and Human Services referred Hims & Hers Health to the Department of Justice for investigation in February 2026. Novo Nordisk has also filed a lawsuit against Hims & Hers alleging deceptive promotion of compounded semaglutide.

Mubboo's Take

The GLP-1 telehealth market is a case study in what happens when consumer demand outpaces regulatory infrastructure. AI tools enabled companies to scale marketing and customer acquisition to hundreds of millions in revenue before regulators could assess the safety and legality of what was being sold. For consumers considering any health product purchased through a telehealth platform, the FDA's actions are a reminder that speed and convenience are not substitutes for regulatory oversight — and that the company with the smoothest checkout experience is not necessarily the one with the safest product.